Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition

Bitget2026/10/19 23:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Iambic Therapeutics director Evan Lockwood Rachlin reported an indirect purchase of 718,750 common shares at $16 per share.
Conversions of preferred stock and Convertible Promissory Notes added 1,927,252 common shares, bringing his reported indirect holdings to 2,646,002 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iambic Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002151678-26-000007), on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition

You may also like

Crypto prices